Several unsuspected systemic metastases were discovered, and some clinical decisions were affected by RAID results. However, in this reviewer's opinion, the study protocols used did not clearly define specificity or sensitivity issues for systemic metastatic disease. Conclusions Clinical studies of RAID in patients with melanoma are in progress. The sensitivity of current techniques using MAb technology is dependent on the volume of the metastatic deposit. Accurate detection of micrometastatic or microinvasive melanoma is the target of future research.
RAID currently seems to be an important adjunct to the diagnosis and treatment of ocular melanoma.
II malignant melanoma, when the lymph nodes are benign or reactive. References Feggi L, Indelli M, Pansiri GC, et al. Nucl Med Commun. Omlor G, Berberich R, Gross G, et al Initial experiences with a new monoclonal antibody in diagnosis of malignant melanomas. Langenbecks Arch Chir.